Meropenem

Chemical formula: C₁₇H₂₅N₃O₅S  Molecular mass: 383.463 g/mol  PubChem compound: 441130

Therapeutic indications

Meropenem is indicated for:

Severe pneumonia

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Severe pneumonia, including hospital and ventilator-associated pneumonia.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Broncho-pulmonary infections in cystic fibrosis

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Bronchopneumonia and additionally at least one of
Meropenem susceptible species
Meropenem susceptible species for which acquired resistance may be a problem
and additionally Cystic fibrosis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Complicated urinary tract infections

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Urinary tract infectious disease and additionally at least one of
Meropenem susceptible species
Meropenem susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Complicated intra-abdominal infections

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Infectious disease of abdomen and additionally at least one of
Meropenem susceptible species
Meropenem susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Intra- and post-partum infections

Population group: women, only adults (18 - 65 years old)

Infectious disease in mother complicating pregnancy, childbirth AND/OR puerperium and additionally at least one of
Meropenem susceptible species
Meropenem susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Complicated skin and soft tissue infections

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Soft tissue infection and additionally at least one of
Meropenem susceptible species
Meropenem susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Acute bacterial meningitis

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Bacterial meningitis and additionally at least one of
Meropenem susceptible species
Meropenem susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Febrile neutropenia

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Febrile neutropenia and additionally at least one of
Meropenem susceptible species
Meropenem susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Meropenem is contraindicated in the following cases:

Hypersensitivity to any carbapenem

Carbapenem allergy

Severe hypersensitivity to betalactam antibacterial agents

at least one of
Allergy to penicillin
Cephalosporin allergy

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2019: MERONEM IV 1g Powder for solution for injection or infusion
Summary of Product Characteristics (SPC) 2023: MEROPENEM Powder for solution for injection / infusion
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈